Axi-Cel OS Benefit Shown For Relapsed/Refractory Large B-Cell Lymphoma
From ASCO 2023 Annual Meeting:
Autologous anti-CD19 CAR T-cell therapy boosts overall survival in patients with early relapsed or refractory large B-cell lymphoma
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.
Login to start reading, or Join ESMO - All articles are Open Access after 6 months.
From ASCO 2023 Annual Meeting:
Autologous anti-CD19 CAR T-cell therapy boosts overall survival in patients with early relapsed or refractory large B-cell lymphoma
From ASCO 2023 Annual Meeting:
Survival outcomes for persistent, recurrent or metastatic cervical cancer are significantly improved with the use of pembrolizumab alongside chemotherapy, regardless of bevacizumab therapy
From ASCO 2023 Annual Meeting:
Interim KEYNOTE-671 findings demonstrate an event-free survival benefit with use of pembrolizumab before and after surgery for patients undergoing treatment for early-stage, non-small-cell lung cancer
From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival
From ESMO Breast Cancer 2023:
Patients who do not achieve a complete response to neoadjuvant therapy for early-stage triple-negative breast cancer and have ctDNA after additional capecitabine are at high risk of recurrence
From ESMO Breast Cancer 2023:
Patients with ER-low breast cancer may have disease with similar behaviours to those of their ER-negative counterparts
From ESMO Breast Cancer 2023:
Obesity is associated with poorer disease-free survival than normal weight after postmenopausal hormone receptor-positive breast cancer for women younger than 60 years, but may not affect older patients
From ESMO Breast Cancer 2023:
The addition of capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with hormone receptor-positive, HER2-negative advanced breast cancer resistant to aromatase inhibitors
From the 2023 AACR Annual Meeting:
RLY-2608, a mutant-selective PI3Kα inhibitor, may offer patients with PIK3CA-mutant solid tumours a chance of treatment without experiencing the toxic effects of non-selective PI3Kα inhibition
From the 2023 AACR Annual Meeting:
Patients with gliomas, gynaecological tumours and pancreatic cancer could benefit from treatment with pemigatinib if they harbour an FGFR mutation
From the 2023 AACR Annual Meeting:
Some children and adolescents with solid tumours harbouring gene alterations may benefit from a combination of olaparib plus ceralasertib
From the 2023 AACR Annual Meeting:
Preliminary results suggest REGN5459 has efficacy as a treatment for patients with heavily pretreated multiple myeloma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.